BioLineRx Ltd.

BLRX · Nasdaq · Israel

Share price · BLRX

$1.15-1.70 (-59.65%) 3M

close as of 2026-11-18 · 24h delayed · vol 295K (22.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BLRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 16 Nov 2026-11.5%
  2. 12 Nov 2026-9.4%
  3. 9 Nov 2026-7.6%
  4. 20 Oct 2026+11.8%
  5. 28 Sep 2026-6.5%
  6. 23 Sep 2026+5.3%
  7. 31 Aug 2026+7.7%
  8. 24 Aug 2026+6.8%
  9. 18 Aug 2026+8.0%
  10. 30 Apr 2026-10.4%

Share of unusual movement by asset

For each asset, the share of BLRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Motixafortide
events and moves
3shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—0%
Sessions with no dated event—100%

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Approved
CXCR4Peptide
Multiple MyelomaPancreatic Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (1)
November 2026 (1)
2026-09-30 Financial ReportEarnings report
Expected report date 2026-11-23 · Fiscal period ending 2026-09-30
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (4)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q2$0.3M$2.3M$7.2M$3.9Mreport ↗

BioLineRx Ltd. reported revenue of $0.3M, down 94.4% YoY, R&D spend of $2.33M, up 4.5% YoY, cash and equivalents of $7.19M, and a net loss of $3.94M for Q2 2025.

Figures only: this period's report disclosed no narrative text

View 3 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-Q2$5.4M$2.2M$9.6M—report ↗
2023-Q2$0$3.0M$10M$19Mreport ↗
2022-Q2—$5.4M$14M$7.4Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.2M$8.1M$3.3M$0.5M-$8.1M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$29M$9.2M$10M$2.3M-$44M operating cash flowreport ↗
2023-FY$4.8M$13M$4.3M$15M-$23M operating cash flowreport ↗
2022-FY$0$18M$11M$6.2M-$26M operating cash flowreport ↗
2021-FY$0$19M$13M$6.8M-$24M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

No Form 4 transactions on file in the stored window.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 12 reporting institutions held 0.0M shares ($45K, 0.4% of shares outstanding).

#InstitutionSharesValue
1XTX Topco Ltd10,941$25K
2RHUMBLINE ADVISERS2,353$5K
3BNP PARIBAS FINANCIAL MARKETS1,800$4K
4WELLS FARGO & COMPANY/MN1,750$4K
5CITIGROUP INC1,728$4K
6UBS Group AG529$1K
7Nemes Rush Group LLC250$575
8MORGAN STANLEY100$230
9OSAIC HOLDINGS, INC.26$59
10Rockefeller Capital Management L.P.12$28
11DANSKE BANK A/S2$5
12Banque Cantonale Vaudoise1$0